The authors claim that the ER-dependent heparanase regulation mechanism works in vivo, but the 15% occurrence of heparanase expression in ER-negative tumours suggests distinct molecular mechanisms are accountable for the increase in heparanase expression in the subgroup of ER-negative breast cancers [30]. The gene discussed is HPSE; the disease is neoplasm.